Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Plain language summary: How safe and effective is long-term treatment with intravenous plasminogen concentrate for people with type 1 plasminogen deficiency?
Journal: Therapeutic advances in hematology
Published: February 23, 2026
L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial.
Journal: Nature cancer
Published: December 30, 2025
Safety and Efficacy of Long-Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: November 12, 2024
Nonhealing Surgical Wounds in a Patient with Plasminogen Deficiency Type 1 Successfully Treated with Intravenous Plasminogen: A Case Report.
Journal: Advances in skin & wound care
Published: June 20, 2024
Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.
Journal: American journal of hematology
Published: December 22, 2023
De novo RUNX1-driven acute myeloid leukemia requiring integrative genetics.
Journal: Cancer genetics
Published: May 10, 2023
Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol.
Journal: Biomedicines
Published: March 26, 2023
KMT2A-CBL fusion in rapidly progressive myeloid disorder.
Journal: Cancer genetics
Published: November 17, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026